Company intelligence / Profile preview

Vincentage

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Vincentage's lead program, VCT220 (now CX11 outside China), is an oral small molecule GLP-1 receptor agonist for obesity and overweight. Phase 2 trials in China showed robust, dose-dependent weight loss of up to 9.7% at highest dose and a favorable safety/tolerability profile, with no serious drug-related adverse events. A Phase 3 registrational trial is underway in China as of late 2024, and ex-China rights have been licensed to Corxel, which has begun a Phase 2 U.S. trial. The company's program has shown efficacy similar to injectable GLP-1 drugs, with oral administration and best-in-class tolerability.[1][2][3][4][5]

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Corxel Pharmaceuticals

Beyond the preview

Go deeper on Vincentage.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vincentage.

Explore the full profile